

August 15, 2025

To whom it may concern

Company name	MedPeer, Inc.
Representative	Representative Director & President, CEO Naoki Goto (Code: 6095, TSE Prime Market)
Inquiries	Director & Executive Officer, CFO Toshio Hirabayashi (TEL. 03-4405-4905)

## Notice Concerning Reduction in the Amount of Stated Capital (Capital Reduction)

MedPeer, Inc. (the “Company”) hereby announces that at the Board of Directors meeting held on August 15, 2025, it resolved to submit a proposal regarding a reduction in the amount of its stated capital (“Capital Reduction”) to the extraordinary general meeting of shareholders scheduled for September 29, 2025 (“Extraordinary General Meeting of Shareholders”), as detailed below.

### 1. Purpose of the Capital Reduction

As part of its management strategy for achieving sustainable growth and the medium-to-long-term enhancement of its corporate value, and with the purpose of maintaining financial health through the application of a tax system appropriate for the scale of the Company’s operations and ensuring a flexible and dynamic capital policy, the Company decided to reduce the amount of its stated capital pursuant to the provisions of Article 447, Paragraph 1 of the Companies Act.

It should be noted that this change to the amount of stated capital will not involve a change in the total number of the Company’s issued shares, and accordingly, there will be no impact on the number of shares held by each shareholder.

Further, there will no change in the amount of the Company’s net assets, nor will there be any change in the amount of net assets per share.

### 2. Details of the Capital Reduction

#### (1) Amount of capital to be reduced

The amount of capital, 2,261,965,050 yen, will be reduced by 2,161,965,050 yen, to 100,000,000 yen.

#### (2) Method of the Capital Reduction

Pursuant to the provisions of Article 447, Paragraph 1 of the Companies Act, the amount of stated capital shall be reduced as set forth above and the entire amount of the reduction shall be appropriated to other capital surplus.

### 3. Schedule for the Capital Reduction

(1)	Resolution at the Board of Directors meeting	Friday, August 15, 2025
(2)	Public notice about creditor objections	Tuesday, August 26, 2025 (tentative date)
(3)	Final day of creditor objection period	Friday, September 26, 2025 (tentative date)
(4)	Resolution at the general meeting of shareholders	Monday, September 29, 2025 (tentative date)
(5)	Effective date	Tuesday, September 30, 2025 (tentative date)

### 4. Outlook

The Capital Reduction will have no impact on the Company’s financial results. This matter is subject to approval of the resolution concerning the Capital Reduction at the Extraordinary General Meeting of Shareholders.

End

<sup>1</sup> This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.